دورية أكاديمية
Gemcitabine and split-dose paclitaxel or docetaxel in metastatic breast cancer: a randomised phase II study.
| العنوان: | Gemcitabine and split-dose paclitaxel or docetaxel in metastatic breast cancer: a randomised phase II study. |
|---|---|
| المؤلفون: | Khoo KS; National Cancer Centre, Singapore, Singapore., Manzoor Zaidi SH, Srimuninnimit V, Song S, Nair R, Ngelangel CA, Bustam A, Reece WH, Lehnert M |
| المصدر: | European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2006 Aug; Vol. 42 (12), pp. 1797-806. Date of Electronic Publication: 2006 Jul 17. |
| نوع المنشور: | Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0959-8049 (Print) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Oxford : Elsevier Science Ltd Original Publication: Oxford ; New York : Pergamon Press, c1990- |
| مواضيع طبية MeSH: | Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, Adolescent ; Adult ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Deoxycytidine/administration & dosage ; Deoxycytidine/adverse effects ; Deoxycytidine/analogs & derivatives ; Docetaxel ; Female ; Humans ; Middle Aged ; Neoplasm Metastasis ; Paclitaxel/administration & dosage ; Paclitaxel/adverse effects ; Taxoids/administration & dosage ; Taxoids/adverse effects ; Treatment Failure ; Gemcitabine |
| مستخلص: | Purpose: The purpose was to evaluate the activity and toxicity of split-dose paclitaxel or docetaxel in combination with gemcitabine in patients with metastatic breast cancer (MBC) who had previously received anthracyclines. Patients and Methods: A total of 210 patients were randomly assigned to one of three treatment arms: gemcitabine 1,250 mg/m(2) Days 1 and 8 and paclitaxel 175 mg/m(2) as a 3-h infusion on Day 1 (GP1); gemcitabine 1,000 mg/m(2) Days 1 and 8 and paclitaxel 100 mg/m(2) as a 1-h infusion on Days 1 and 8 (GP2); gemcitabine 1,000 mg/m(2) Days 1 and 8 and docetaxel 40 mg/m(2) as a 1-h infusion on Days 1 and 8 (GD). Cycles were repeated every 3 weeks. Results: For the 204 patients evaluable for response assessment, the response rates were 48.6% for GP1, 52.2% for GP2, and 52.3% for GD. Median response duration, time to treatment failure, and time to progression (TTP) were similar in each arm. Median TTP for GP1, GP2 and GD was 7.5, 7.0 and 7.4 months, respectively. For the 208 patients evaluable for safety, the most common grade 3/4 toxicity for each regimen was neutropaenia, with 64%, 57%, and 68% for GP1, GP2, and GD, respectively. Grade 4 neutropaenia, grade 3/4 anaemia, febrile neutropaenia, and diarrhoea were more common in the docetaxel arm, as was the use of intravenous antibiotics and blood transfusions. Conclusion: The study confirmed the high activity of gemcitabine-taxane combinations in MBC. Split-dose paclitaxel had similar activity and toxicity to the 3-weekly administration. The split-dose docetaxel regimen had similar activity to the paclitaxel combinations though associated with higher toxicity. |
| المشرفين على المادة: | 0 (Taxoids) 0W860991D6 (Deoxycytidine) 15H5577CQD (Docetaxel) P88XT4IS4D (Paclitaxel) 0 (Gemcitabine) |
| تواريخ الأحداث: | Date Created: 20060719 Date Completed: 20061017 Latest Revision: 20221207 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1016/j.ejca.2006.05.001 |
| PMID: | 16846734 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 0959-8049 |
|---|---|
| DOI: | 10.1016/j.ejca.2006.05.001 |